Company Overview and News
Triumph Group, Inc.(NYSE:TGI) announced today that it was awarded two contract extensions from General Dynamics Ordnance and Tactical Systems for the production of specially machined guided missile parts. The contracts, which are expected to generate sales totaling more than $11 million, are for machining and forging of parts and components on the Lockheed Martin HELLFIRE Romeo guided missile systems.
A month has gone by since the last earnings report for Jack In The Box (JACK - Free Report) . Shares have lost about 5.8% in that time frame, underperforming the S&P 500.
ALLY TGI KORS JACK
A month has gone by since the last earnings report for Aerie Pharmaceuticals (AERI - Free Report) . Shares have lost about 10.6% in that time frame, underperforming the S&P 500.
ALLY TGI KORS AERI
A month has gone by since the last earnings report for Liberty Global (LBTYA - Free Report) . Shares have lost about 5.5% in that time frame, underperforming the S&P 500.
LBTYK ALLY LILAB LBTY TGI KORS LILAK LBTYB LBTYA LILA
A month has gone by since the last earnings report for Wright Medical Group (WMGI - Free Report) . Shares have lost about 1.2% in that time frame, underperforming the S&P 500.
ALLY TGI KORS
A month has gone by since the last earnings report for New York Times Co. (NYT - Free Report) . Shares have lost about 0.2% in that time frame, underperforming the S&P 500.
ALLY TGI KORS NYTAB
It has been about a month since the last earnings report for Dun & Bradstreet (DNB - Free Report) . Shares have added about 0.8% in that time frame, underperforming the S&P 500.
DNB ALLY TGI KORS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to TGI / Triumph Group, Inc. on message board site Silicon Investor.
as of ET